RapidMeta · Living Evidence Synthesis

It began with one molecule.

The question was narrow — does finerenone protect the failing kidney? — and the answer was built not by mining PDFs, but by reading the trial registry itself, then rebuilt each time the evidence moved. That one living review became a method. The portfolio now runs to 947 living reviews — of which 617 are provenance-verified (only the curated 17 benchmark apps are externally validated) — each pools registered trials traced to their publications (PMID + registry), and the curated core is benchmarked against published meta-analyses and R metafor. The remainder are live but provenance-pending, shown in the dashboard without a pooled estimate. Open any one, and follow the evidence to its source.

Mahmood Ahmad · 947 living reviews · 617 provenance-verified · Filterable dashboard →

From registries, not PDFs

Trials, arms and outcomes are read from structured registry data — so a review is refreshed as the evidence grows, not frozen at the date of publication.

Cochrane-grade, in the browser

REML and HKSJ pooling, prediction intervals, network meta-analysis, GRADE — the full Cochrane v6.5 apparatus, with nothing to install.

Auditable to the trial

Every estimate is cross-checked against R metafor and the published record — and every number traces back to the registration it came from.

BrowseAllergy & Immunology Cardiology Dermatology Endocrinology Gastroenterology Hematology Hepatology Infectious Disease Nephrology Neurology Oncology Ophthalmology Psychiatry Respiratory Rheumatology Urology Vaccines & Global Health Women's Health

Allergy & Immunology

Balanced Crystalloids vs Saline (ICU)Critical care · 3 RCTs · PLUS/BaSICS/SMART Sugammadex vs NeostigmineAnaesthesia · 2 RCTs · residual NMB Conservative vs Liberal Oxygen (ICU)Critical care · 4 RCTs · HOT-ICU/ICU-ROX/LOCO2/Oxygen-ICU RRT Timing in AKI (early vs delayed)Critical care · 4 RCTs · STARRT-AKI/AKIKI/ELAIN/IDEAL-ICU Omalizumab in food allergyAudit-first build · 4 trials · AACT-verified · k>=3 Palforzia OIT in peanut allergyAudit-first build · 3 trials · AACT-verified · k>=3 Viaskin Peanut patch immunotherapyAudit-first build · 2 trials · AACT-verified · k>=3

Cardiology

Dermatology

Endocrinology

Gastroenterology

Hematology

Hepatology

Infectious Disease

Nephrology

Neurology

Oncology

Ophthalmology

Aflibercept in DMEAudit-first build · 3 trials · AACT-verified · k>=3 Avacincaptad pegol in GA (broader)Audit-first build · 2 trials · AACT-verified · k>=3 Faricimab in DMEAudit-first build · 3 trials · AACT-verified · k>=3 Faricimab in RVO macular oedemaAudit-first build · 2 trials · AACT-verified · k>=3 Ranibizumab in DRAudit-first build · 2 trials · AACT-verified · k>=3

Psychiatry

Respiratory

Rheumatology

Urology

Tadalafil daily in BPH/EDAudit-first build · 3 trials · AACT-verified · k>=3 Vibegron in OABAudit-first build · 3 trials · AACT-verified · k>=3

Vaccines & Global Health

Women's Health

Other / Cross-Specialty

Physical Rehabilitation in Older Adults NMA — REHAB-HF + LIFE + ICAREPublished: REHAB-HF SPPB +1.5 in older HF; LIFE HR 0.82 mobility disability sedentary elders; ICARE WMFT non-superior post-stroke, k=3 (post-2010 physiotherapy NMA) Alemtuzumab induction in transplantAudit-first build · 2 trials · AACT-verified · k>=3 Aprepitant in PONVAudit-first build · 2 trials · AACT-verified · k>=3 Rituximab in AAV / IgG4-RDAudit-first build · 2 trials · AACT-verified · k>=3 Sotagliflozin in T1DAudit-first build · 4 trials · AACT-verified · k>=3

Utilities & Cross-Portfolio Tools

Mortality Atlas25-class pooled ACM / CV-death HRs LivingMeta shellGeneric browser MA Meta DashboardCross-app aggregator MetaExtractData extraction tool AutoGRADECertainty-of-evidence grader AutoManuscriptPRISMA-2020 draft generator TrialRadarCT.gov trial surveillance

E156 submission (Finerenone micro-paper)

E156 micro-paper — interactive reader Paper (markdown) Protocol (markdown) Published-meta benchmark JSONSource for cross-validation chips

All 77 pooled results — quick portfolio scan

Topic	Specialty	k	Published pool (95% CI)	Protocol
ARNI in HF	Cardio (HF)	3	HR 0.84 (0.77–0.91)	v1.0
SGLT2i in HF	Cardio (HF)	2	HR 0.77 (0.71–0.84)	v1.0
IV Iron in HFrEF	Cardio (HF)	4	HR 0.84 (0.74–0.96)	v1.0
Incretins in HFpEF	Cardio (HF)	3	HR 0.41 (0.22–0.79)	v1.0
Mavacamten HCM	Cardio (HCM)	3	OR 6.67 (2.09–21.30)	v1.0
ATTR-CM	Cardio (CM)	4	HR 0.71 (0.59–0.86)	v1.0
Finerenone CKD	Cardio (Renal)	2	HR 0.86 (0.78–0.95)	v1.0
SGLT2i in CKD	Cardio (Renal)	3	HR 0.68 (0.60–0.77)	v1.0
PCSK9 mAbs	Cardio (Lipid)	2	HR 0.85 (0.79–0.92)	v1.0
Bempedoic Acid	Cardio (Lipid)	1	HR 0.87 (0.79–0.96)	v1.0
	Cardio (Lipid)	3	LDL MD −50.7% (−53.1 to −48.3)	v1.0
Colchicine in ASCVD	Cardio (Anti-inf)	2	HR 0.75 (0.61–0.91)	v1.0
Rivaroxaban Vascular	Cardio (Anticoag)	4	HR 0.85 (0.77–0.94)	v1.0
Cangrelor in PCI	Cardio (Antiplatelet)	3	OR 0.81 (0.71–0.91)	v1.0
DOAC vs Warfarin in AF	Cardio (Anticoag)	4	HR 0.81 (0.73–0.91)	v1.0
DOAC in Cancer VTE	Cardio (Anticoag)	4	HR 0.55 (0.30–1.00)	v1.0
GLP-1 RA CVOTs	Cardio (DM)	8	HR 0.88 (0.84–0.94)	v1.0
Intensive BP	Cardio (BP)	5	HR 0.79 (0.71–0.87)	v1.0
	Cardio (BP)	5	SBP MD −5.12 mmHg (−6.85 to −3.40)	v1.0
Ablation in AF+HF	Cardio (Rhythm)	4	HR 0.77 (0.64–0.93)	v1.0
TMVR Functional MR	Cardio (Structural)	3	HR 0.72 (0.55–0.95)	v1.0
	Neurology	3	CDR-SB MD −0.45 (−0.65 to −0.25)	v1.0
	Neurology	3	MMD MD −1.7 (−2.0 to −1.4)	v1.0
CDK4/6 in mBC	Oncology (Breast)	3	PFS HR 0.56 (0.48–0.64)	v1.0
ARPI in mHSPC	Oncology (Prostate)	4	OS HR 0.67 (0.61–0.74)	v1.0
PARP in Ovarian	Oncology (Ovarian)	3	PFS HR 0.52 (0.42–0.64)	v1.0
JAK-i in UC	Gastroenterology	3	OR 3.2 (2.4–4.3)	v1.0
Biologics in Asthma	Respiratory	4	Rate ratio 0.52 (0.44–0.61)	v1.0
	Respiratory	3	ppFEV1 MD +11.5 pp (9.5–13.5)	v1.0
	Endocrinology	3	HbA1c MD −1.59% (−2.18 to −1.01)	v1.0
IL-23 in Plaque Psoriasis	Dermatology	3	PASI 90 OR 20.9 (11.7–37.3)	v1.0
	Endocrinology (Obesity)	3	weight MD −11.8% (−13.2 to −10.5)	v1.0
BCMA CAR-T in RRMM	Oncology (Heme)	2	PFS HR 0.55 (0.35–0.84)	v1.0
Romosozumab in Osteoporosis	Endocrinology (Bone)	3	vertebral fx RR 0.32 (0.16–0.68)	v1.0
Triple Therapy in COPD	Respiratory	3	exacerbation RR 0.76 (0.65–0.88)	v1.0
Dupilumab in Atopic Dermatitis	Dermatology	3	IGA 0/1 OR 3.55 (2.84–4.44)	v1.0
Anti-CD20 in Relapsing MS	Neurology	4	ARR RR 0.49 (0.42–0.58)	v1.0
Risankizumab in Crohn's	Gastroenterology	3	remission OR 1.73 (1.15–2.60)	v1.0
RSV Vaccines ≥60	Respiratory (Vaccines)	3	RSV-LRTD RR 0.20 (0.14–0.29)	v1.0
Cabotegravir LA HIV PrEP	Infectious Disease (HIV)	2	HIV HR 0.22 (0.11–0.45)	v1.1
COVID-19 Oral Antivirals	Infectious Disease (COVID)	2	hosp/death RR 0.30 (0.06–1.45)	v1.1
Venetoclax in Untreated AML	Haematology	2	OS HR 0.77 (0.68–0.87)	v1.1
CAR-T 2L in R/R DLBCL	Haematology	3	EFS HR 0.76 (0.58–0.99)	v1.1
JAK Inhibitors in RA	Rheumatology	3	ACR20 RR 1.66 (1.53–1.81)	v1.1
	Endocrinology	3	HbA1c MD −0.21% (−0.30 to −0.12)	v1.1
Nirsevimab for Infant RSV	Infectious Disease (Paed)	3	RSV-LRTI RR 0.21 (0.13–0.33)	v1.1
Upadacitinib in Crohn	Gastroenterology	3	remission RR 1.99 (1.53–2.60)	v1.1
	Ophthalmology	2	BCVA MD +0.37 letters (−0.65 to +1.39)	v1.1
	Women's Health	2	VMS MD −2.15/day (−2.71 to −1.59)	v1.1
Lenacapavir Q6M HIV PrEP	Infectious Disease (HIV)	2	HIV RR 0.07 (0.01–0.32)	v1.1
Dupilumab in Eosinophilic COPD	Respiratory	2	exacerbation RR 0.68 (0.59–0.78)	v1.1
Mirikizumab in UC	Gastroenterology	2	remission RR 1.91 (1.56–2.35)	v1.1
	Ophthalmology	2	GA MD −0.38 mm (−0.62 to −0.14)	v1.1
	Psychiatry	2	PANSS MD −8.95 (−11.9 to −6.0)	v1.1
	Ophthalmology	2	BCVA MD +0.75 letters (−0.24 to +1.74)	v1.1
	Neurology	2	mNIS+7 MD −31.3 (−36.7 to −26.0)	v1.1
Acalabrutinib in CLL (ELEVATE-TN + ASCEND)	Haematology	2	PFS HR 0.25 (0.19–0.33)	v1.1
PPAR modulators in PBC 2L	Hepatology	2	biochemical RR 5.55 (1.32–23.37)	v1.1
177Lu-PSMA-617 in mCRPC	Oncology (Prostate)	2	rPFS HR 0.42 (0.34–0.51)	v1.1
Sotagliflozin in HF / CKD-T2D	Cardiology (HF)	2	total CV HR 0.72 (0.63–0.82)	v1.1
	Psychiatry	2	MADRS MD −3.82 (−6.28 to −1.35)	v1.1
SGLT2i CVOT 3P-MACE (class pool)	Cardiology (Diabetes)	4	3P-MACE HR 0.91 (0.85–0.98)	v1.1
IO + Chemo 1L NSCLC	Oncology (Lung)	4	OS HR 0.81 (0.74–0.89)	v1.1
EVT 6-24h Extended-Window Stroke	Neurology (Stroke)	3	mRS 0-2 RR 2.31 (1.28–4.19)	v1.1
Tenecteplase vs Alteplase AIS	Neurology (Stroke)	3	mRS 0-1 RR 1.06 (1.00–1.12)	v1.1
Thrombectomy in Basilar-Artery Occlusion	Neurology (Stroke)	3	mRS 0-3 RR 1.62 (1.12–2.35)	v1.1
Thrombectomy in Large-Core Infarct	Neurology (Stroke)	3	mRS 0-2 RR 2.45 (1.79–3.35)	v1.1
PARP + ARPI in 1L mCRPC	Oncology (Prostate)	3	rPFS HR 0.66 (0.58–0.76)	v1.1
Belimumab in SLE (BLISS Programme)	Rheumatology	4	composite RR 1.29 (1.17–1.42)	v1.1
Cannabidiol in Dravet/LGS	Neurology (Epilepsy)	4	responder RR 1.88 (1.46–2.42)	v1.1
Fenfluramine in Dravet/LGS	Neurology (Epilepsy)	3	responder RR 4.64 (2.03–10.58)	v1.1
	Endocrinology (Obesity)	3	weight MD −16.71% (−21.93 to −11.48)	v1.1
JAKi in Atopic Dermatitis	Dermatology	4	IGA 0/1 RR 7.10 (4.86–10.40)	v1.1
	Cardiology (HF/CM)	—	v13.0 Cochrane v6.5	v1.0
ACS Antiplatelet NMA (Clopidogrel / Ticagrelor / Prasugrel)	Network MA	—	v13.0 Cochrane v6.5	v1.0
	Network MA	—	v13.0 Cochrane v6.5	v1.0
ADC NMA in HER2-Low Metastatic Breast Cancer	Network MA	—	v13.0 Cochrane v6.5	v1.0
ADC NMA in HER2+ MBC 2L+ PFS v1.2 (split-TPC, transitivity-restored tree)	Network MA	—	v13.0 Cochrane v6.5	v1.0
	Cardiology (HCM)	—	v13.0 Cochrane v6.5	v1.0
	Network MA	—	v13.0 Cochrane v6.5	v1.0
JAK Inhibitors in Severe Alopecia Areata — NMA	Network MA	—	v13.0 Cochrane v6.5	v1.0
Anti-CD20 Therapies in Relapsing MS — NMA	Network MA	—	v13.0 Cochrane v6.5	v1.0
AR Pathway Inhibitors in Metastatic Hormone-Sensitive Prostate Cancer	Oncology (Prostate)	—	v13.0 Cochrane v6.5	v1.0
Atopic Dermatitis Biologics + JAKi NMA	Network MA	—	v13.0 Cochrane v6.5	v1.0
	Ophthalmology	—	v13.0 Cochrane v6.5	v1.0
Mass Azithromycin for Under-5 Mortality in Sub-Saharan Africa	Infectious Disease (Paediatric MDA)	—	v13.0 Cochrane v6.5	v1.0
Bimekizumab (IL-17A/F Dual) in Plaque Psoriasis	Dermatology	—	v13.0 Cochrane v6.5	v1.0
	Oncology (Breast)	—	v13.0 Cochrane v6.5	v1.0
Modern Cardiorenal Therapies in CKD (+/- T2D) NMA	Network MA	—	v13.0 Cochrane v6.5	v1.0
Crohn's Disease Biologics Induction-Remission NMA	Network MA	—	v13.0 Cochrane v6.5	v1.0
CFTR Modulator Ladder in Cystic Fibrosis NMA	Network MA	—	v13.0 Cochrane v6.5	v1.0
CGRP mAb Class NMA for Episodic Migraine Prevention	Network MA	—	v13.0 Cochrane v6.5	v1.0
	Neurology (DMD)	—	v13.0 Cochrane v6.5	v1.0
DOAC Class NMA vs Warfarin for Stroke Prevention in AF	Network MA	—	v13.0 Cochrane v6.5	v1.0
DOAC Class NMA vs Warfarin for Acute VTE Treatment	Network MA	—	v13.0 Cochrane v6.5	v1.0
Dolutegravir First-Line ART in Sub-Saharan Africa	Infectious Disease (HIV)	—	v13.0 Cochrane v6.5	v1.0
	Neurology (AD)	—	v13.0 Cochrane v6.5	v1.0
	Oncology (Breast)	—	v13.0 Cochrane v6.5	v1.0
Ensifentrine for COPD (PDE3/4 Inhibitor)	Respiratory	—	v13.0 Cochrane v6.5	v1.0
Etrasimod (S1P Modulator) in Moderate-Severe Ulcerative Colitis	Gastroenterology	—	v13.0 Cochrane v6.5	v1.0
GLP-1 RA Class NMA for MACE in T2D CV-Outcomes	Network MA	—	v13.0 Cochrane v6.5	v1.0
Incretin Therapies in MASH/NASH — NMA	Network MA	—	v13.0 Cochrane v6.5	v1.0
First-Line Hepatocellular Carcinoma — IO Combination NMA	Network MA	—	v13.0 Cochrane v6.5	v1.0
HER2-Low Metastatic BC ADCs — NMA (T-DXd / Dato-DXd / Sacituzumab)	Network MA	—	v13.0 Cochrane v6.5	v1.0
HF Quadruple Therapy NMA (SGLT2i / ARNI / MRA / β-blocker)	Network MA	—	v13.0 Cochrane v6.5	v1.0
Long-Acting Injectable PrEP NMA (Cabotegravir + Lenacapavir)	Network MA	—	v13.0 Cochrane v6.5	v1.0
	Oncology (Breast)	—	v13.0 Cochrane v6.5	v1.0
Incretin Therapies in HFpEF Ultra-Precision	Other	—	v13.0 Cochrane v6.5	v1.0
	Renal	—	v13.0 Cochrane v6.5	v1.0
Oral JAK Inhibitors NMA in Moderate-Severe Atopic Dermatitis	Network MA	—	v13.0 Cochrane v6.5	v1.0
KRAS G12C Inhibitors in Pretreated KRAS-G12C-Mutated Advanced NSCLC NMA	Network MA	—	v13.0 Cochrane v6.5	v1.0
Lebrikizumab (IL-13 mAb) in Moderate-Severe Atopic Dermatitis	Dermatology	—	v13.0 Cochrane v6.5	v1.0
Malaria Vaccines NMA (RTS,S + R21 / Matrix-M)	Network MA	—	v13.0 Cochrane v6.5	v1.0
Acute Migraine Treatment NMA (Gepants / Ditans / Triptans)	Network MA	—	v13.0 Cochrane v6.5	v1.0
	Haematology	—	v13.0 Cochrane v6.5	v1.0
First-Line Multiple Myeloma — Anti-CD38 Quadruplet NMA	Network MA	—	v13.0 Cochrane v6.5	v1.0
Obesity Pharmacotherapy NMA (GLP-1, GIP/GLP-1, Amylin)	Network MA	—	v13.0 Cochrane v6.5	v1.0
PAH Advanced Therapy NMA (Sotatercept / Selexipag / Riociguat / Macitentan)	Network MA	—	v13.0 Cochrane v6.5	v1.0
Non-Statin LDL-Lowering CVOT NMA for MACE	Network MA	—	v13.0 Cochrane v6.5	v1.0
Psoriatic Arthritis Biologics NMA (TNFi / IL-17 / IL-23 / JAKi)	Network MA	—	v13.0 Cochrane v6.5	v1.0
First-Line Advanced RCC — IO Doublet & IO+TKI NMA	Network MA	—	v13.0 Cochrane v6.5	v1.0
	Hepatology	—	v13.0 Cochrane v6.5	v1.0
	Haematology	—	v13.0 Cochrane v6.5	v1.0
Severe Eosinophilic/T2-High Asthma Biologics NMA	Network MA	—	v13.0 Cochrane v6.5	v1.0
SGLT2 Inhibitor Class NMA in Heart Failure	Network MA	—	v13.0 Cochrane v6.5	v1.0
	Cardiology (PAH)	—	v13.0 Cochrane v6.5	v1.0
	Renal	—	v13.0 Cochrane v6.5	v1.0
Axial Spondyloarthritis Biologics NMA (TNFi / IL-17 / JAKi)	Network MA	—	v13.0 Cochrane v6.5	v1.0
	Endocrinology (T1D)	—	v13.0 Cochrane v6.5	v1.0
	Infectious Disease (Vaccine)	—	v13.0 Cochrane v6.5	v1.0
UC Biologics/Advanced-Therapy Induction-Remission NMA	Network MA	—	v13.0 Cochrane v6.5	v1.0
	Renal	—	v13.0 Cochrane v6.5	v1.0
	Oncology (Glioma)	—	v13.0 Cochrane v6.5	v1.0
	Neurology (hATTR)	—	v13.0 Cochrane v6.5	v1.0
Zolbetuximab in CLDN18.2+ HER2- Gastric/GEJ Adenocarcinoma (1L)	Oncology (Gastric)	—	v13.0 Cochrane v6.5	v1.0
Global Health & Africa-Focused (post-2010 drugs/interventions)
	Infectious Disease (TB)	3	unfavorable RR 0.23 (0.15-0.36)	v0.1
Single-Dose HPV Vaccination NMA (Africa)	Infectious Disease (Vaccine)	2	bivalent VE 97.5% (81.7-99.7)	v0.1
ACT NMA for Uncomplicated Falciparum Malaria	Infectious Disease (Malaria)	5	PCR-corrected ACPR >90% all ACTs	v0.1
	Infectious Disease (Malaria)	2	0.4 mg/kg vs AL-only RR 0.157 (0.090-0.273)	v0.1
PPH Prevention & Treatment NMA	Maternal Health	3	E-MOTIVE bundle RR 0.40 (0.32-0.50)	v0.1
	Hematology	3	hydroxyurea VOC RR 0.43; CTX001 VF12 93.5%	v0.1
	Infectious Disease (HIV)	1 (3-arm)	DTG/TDF VL suppression 90% vs EFV 79%	v0.1
	Infectious Disease (TB)	1	HR 0.97 (0.59-1.61) non-inferior; completion 97% vs 90%	v0.1
	Infectious Disease (Cholera)	1	24-mo VE 39% (23-52); n=204,438	v0.1
Pan-Genotypic HCV DAA Therapy NMA	Hepatology	3	SVR12 99% across genotypes	v0.1
	Digital Health (HIV)	1	adherence RR 1.23 (1.06-1.43)	v0.1
HIV PrEP for AGYW in sub-Saharan Africa	Infectious Disease (HIV/AGYW)	2	oral PrEP adherence 23% vs 12%; vaginal TFV gel NULL	v0.1
	Infectious Disease (TB)	1	unfavorable RR 1.22 (0.81-1.84); NI met	v0.1
TAF vs TDF for Chronic Hepatitis B (Buti+Chan 2016)	Hepatology	2	HBV-DNA <29 IU/mL ~94% TAF vs ~93% TDF (HBeAg-); ~64% vs ~67% (HBeAg+); NI met both	v0.1
	Infectious Disease (Ebola)	2	VE 100% (95% CI 79.3-100) Guinea ring; STRIVE 0/0 (outbreak waned)	v0.1
	Pediatric Nutrition	1	ComPAS 51.9% vs Standard 50.9% (diff +1.0pp, 97.5% CI -5.5 to +7.6); NI met; 50% less RUTF	v0.1
	Pediatric Infectious Disease	1	dose-NI +0.2pp; duration-NI +0.1pp; BOTH NI met (8pp margin)	v0.1
	Neglected Tropical Disease	1	cure 76% L-PZQ vs 77.5% Biltricide; WHO 2024 PQ basis	v0.1
HIV PrEP NMA (HPTN 083 + 084 + DISCOVER)	HIV / Prevention	3	HPTN 083 HR 0.34; HPTN 084 HR 0.12 (SSA women); DISCOVER NI	v0.1
Malaria Vaccine NMA (RTS,S + R21/MM Phase 2b + Phase 3)	Vaccinology	3	RTS,S VE 36% 4y; R21 Ph2b 77%; R21 Ph3 75% std / 68% seasonal	v0.1
TB Preventive Treatment NMA (1HP vs 3HP vs 9H) — pending	Infectious Disease (TB)	3	BRIEF-TB 1HP NI; PREVENT TB 3HP CIR 0.44; iAdhere SAT NI to DOT	pending
MDR-TB Shortened-Regimen NMA (TB-PRACTECAL + Nix-TB + ZeNix)	Infectious Disease (TB)	3	TB-PRACTECAL BPaLM RR 0.22; Nix-TB 90% favourable XDR; ZeNix Lzd 600mg/26w NI	v0.1
Postpartum Hemorrhage NMA (E-MOTIVE + WOMAN + CHAMPION)	Maternal Health	3	E-MOTIVE bundle RR 0.40; WOMAN TXA RR 0.81 death; CHAMPION carbetocin NI	v0.1
Pediatric HIV ART NMA (ODYSSEY + CHAPAS-3 + ARROW)	Pediatric HIV	3	ODYSSEY DTG HR 0.61 vs SOC; CHAPAS-3 ABC backbone; ARROW clinical-monitoring NI	v0.1
African Rotavirus Vaccine NMA (Rotarix + RotaTeq + Rotasiil)	Vaccinology	3	Rotarix-Africa VE 61%; RotaTeq-Africa VE 39%; Rotasiil-Niger VE 67%	v0.1
HPV Vaccine Schedules NMA (PATRICIA + FUTURE II + KEN SHE)	Vaccinology	3	PATRICIA Cervarix 93%; FUTURE II Gardasil-4 98%; KEN SHE single-dose 97.5%	v0.1
Severe African Pediatric Febrile Illness NMA (AQUAMAT + FEAST + TRACT)	Pediatrics / Severe Illness	3	AQUAMAT artesunate RR 0.78; FEAST bolus RR 1.45 harm; TRACT 30 vs 20 mL/kg NS	v0.1
Cryptococcal Meningitis NMA in African HIV+ Adults (ACTA + AMBITION-cm + COAT)	Infectious Disease (HIV/Crypto)	3	ACTA 1w-amB+5FC HR 0.77; AMBITION-cm single-dose L-amB NI; COAT early-ART HR 1.73 HARM	v0.1
SARS-CoV-2 Rapid Antigen for COVID-19 (DTA)	Infectious Disease (COVID / DTA)	6*	Sens/Spec bivariate vs RT-PCR (k=5 primary)	spec
D-dimer for PE rule-out (DTA)	Cardiovascular / VTE (DTA)	6*	Sens/Spec bivariate vs CTPA + 3-mo follow-up	spec
GeneXpert Ultra for Pulmonary TB (DTA)	Infectious Disease (TB / DTA)	5*	Sens/Spec bivariate (mada 7/7 EXACT)	spec
hs-cTn 0/1h for NSTEMI rule-out (DTA)	Cardiovascular / ACS (DTA)	5*	Sens/Spec bivariate vs adjudicated AMI (k=5 primary)	spec
mpMRI (PI-RADS) for csPCa (DTA)	Oncology (Prostate / DTA)	6*	Sens 91% / Spec 51% vs histology (k=5 primary)	spec
Plasma p-tau217 for Alzheimer's (DTA)	Neurology (AD / DTA)	5*	Sens/Spec bivariate vs amyloid-PET + CSF Aβ42/40 (k=4 primary)	spec